To include your compound in the COVID-19 Resource Center, submit it here.

Teva's SD-809 passes latest tardive dyskinesia test

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two doses of SD-809 deutetrabenazine met the primary endpoint in the Phase III AIM-TD study to treat moderate to severe tardive dyskinesia. The company intends to submit

Read the full 331 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE